SELLAS Life Sciences Group, Inc.

For the period ended Sep 30, 2025. Filed Nov 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 12, 2025

SLS$8.42+6.9%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Unaudited Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024

CONSOLIDATED BALANCE SHEETS

(Amounts in thousands, except share and per share data)

	September 30, 2025	December 31, 2024
ASSETS
Current assets:
Cash and cash equivalents	$44,320	$13,886
Restricted cash and cash equivalents	100	100
Prepaid expenses and other current assets	4,631	2,341
Total current assets	49,051	16,327
Operating lease right-of-use assets	556	925
Goodwill	1,914	1,914
Deposits and other assets	34	266
Total assets	$51,555	$19,432
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$2,305	$3,500
Accrued expenses and other current liabilities	3,021	5,466
Operating lease liabilities	599	544
Total current liabilities	5,925	9,510
Operating lease liabilities, non-current	—	457
Total liabilities	5,925	9,967
Commitments and contingencies (Note 5)
Stockholders’ equity:
Common stock, $0.0001 par value; 350,000,000 shares authorized, 125,078,525 and 73,977,459 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively	12	7
Additional paid-in capital	312,948	257,583
Accumulated deficit	(267,330)	(248,125)
Total stockholders’ equity	45,630	9,465
Total liabilities and stockholders’ equity	$51,555	$19,432

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.